EGFR and medullary thyroid gland carcinoma: Vandetanib, a TKI that inhibits EGFR as well as VEGFR and RET, is approved for the treatment of advanced MTC but the impact of EGFR inhibition in this disease is unknown and to date, there is limited data about its activity in the treatment of DTC, although clinical trials are presently underway [5,27].